---
layout: post
title: "常山药业：依诺肝素钠注射液获得玻利维亚注册批文"
date: 2022-01-13 19:04:39 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.300255" data-code="300255|0|2" data-code2="300255|0|80|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.300255&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 300255_0" data-code="K 300255|0|2" data-code2="K 300255|0|80|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>常山药业(300255)1月13日晚间公告，公司依诺肝素钠注射液近日获得玻利维亚注册批文，依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201132247031382>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)